A New York City-based biotechnology startup is publicly arguing that the worldwide prohibition on creating gene-edited babies deserves a second look, positioning itself at the center of one of the most contentious debates in modern science. The company, Origin Genomics, says its research is aimed at repairing defective genes in human embryos, and it contends that the potential benefits of the technology for families battling devastating inherited disorders may now outweigh the risks that led to a near-universal moratorium.
The effort is being led by Cathy Tie, the founder and chief executive of Origin Genomics, who recently gave NPR an exclusive tour of the company's laboratory facilities. Tie asked that the precise location of the labs be withheld, citing security concerns — a request that underscores the sensitivity surrounding her company's work. During the visit, she wore a white lab coat bearing her name and the startup's logo, and she guided a reporter, photographer and videographer through the space where the company is testing its gene-repair technology.
Inside the lab, Tie put on blue rubber gloves and pointed to a gray metal tank sitting on the floor, which she described as looking like an oversized thermos. She explained that it is a cryogenic storage unit filled with liquid nitrogen, and that it serves as the repository for the company's embryos. When she twisted open the black lid, white fog spilled out from the supercooled liquid inside. Tie then carefully withdrew a long metal rod, which held frosted glass tubes at its end. She noted that the rod held four tubes, and that each tube is capable of holding as many as ten embryos.
The embryos stored in that tank were donated by couples whose families have suffered for generations from life-threatening genetic disorders — conditions that have shaped their most personal decisions about having children. According to the report, a husband and wife who donated some of those embryos later spoke with NPR about their hope of one day having healthy children with the assistance of gene editing. Their story illustrates the human stakes behind a debate that is often conducted in the abstract language of bioethics and regulation.
Making gene-edited babies is currently illegal in many countries, including the United States, where federal law and regulatory policy effectively bar the implantation of genetically modified embryos for the purpose of creating a pregnancy. The prohibition stems in large part from the 2018 case of Chinese scientist He Jiankui, who shocked the international scientific community by announcing the birth of twin girls whose embryos he had edited. That episode triggered widespread condemnation, calls for a global moratorium and a renewed push to enforce existing restrictions.
Despite that legal landscape, Origin Genomics is pressing ahead with laboratory research it says is designed to demonstrate that the benefits of editing disease-causing genes in human embryos can exceed the risks. The company's scientists extract stem cells from donated embryos in order to test their technology for repairing defective genes, according to the source material. The work is confined to the lab for now, but the company's public posture signals a willingness to challenge the consensus that editing the human germline — changes that would be passed down to future generations — should remain off-limits.
Supporters of germline editing argue that it could one day spare families from passing on conditions such as Huntington's disease, cystic fibrosis or certain forms of inherited cancer. For parents who carry such mutations, the alternatives are limited: they may choose not to have biological children, rely on embryo screening and selection, or use donor gametes. Gene editing, in theory, would allow them to have genetically related children free of the mutation. Critics counter that the technology remains unsafe, that unintended edits could harm children in ways that cannot be anticipated, and that legalizing the practice would open the door to designer babies and deepen social inequality.
The debate has taken on new urgency as gene-editing tools have grown more precise and more widely accessible. The CRISPR system, which earned its discoverers the Nobel Prize in Chemistry in 2020, made targeted genetic changes dramatically easier and cheaper, and a wave of newer editing techniques has further expanded what is possible in the laboratory. At the same time, oversight remains fragmented: some countries have explicit bans, others have guidelines without teeth, and enforcement across borders is difficult when research can be conducted in jurisdictions with permissive rules.
Origin Genomics is not the only actor pushing at those boundaries. Several scientists and bioethicists have in recent years called for a more nuanced conversation about heritable genome editing, arguing that a blanket prohibition may prove unsustainable as the science matures and as public attitudes shift. International bodies, including the World Health Organization, have urged caution and emphasized the need for broad societal consensus before any clinical use of germline editing. The company's argument — that the balance of benefit and risk should be reassessed — places it squarely within that emerging, contested conversation.
For now, the embryos in Origin Genomics' liquid nitrogen tank remain frozen, and the company's work remains experimental. But the startup's decision to invite journalists into its labs, and its willingness to say aloud what much of the scientific establishment has treated as taboo, mark a notable moment in the debate. Whether regulators, researchers and the public ultimately agree that it is time to reconsider the ban may depend on whether Origin and others can produce evidence that editing embryos can be done safely — and on how society weighs the promise of preventing suffering against the perils of altering the human inheritance.
(0)